Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California. Show more

10880 WILSHIRE BOULEVARD, LOS ANGELES, CA, UNITED STATES, 90024, Los Angeles, CA, 90024, USA

https://www.pumabiotechnology.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

397.5M

52 Wk Range

$3.03 - $8.75

Previous Close

$7.81

Open

$7.79

Volume

79,218

Day Range

$7.75 - $7.86

Enterprise Value

320.1M

Cash

36.19M

Avg Qtr Burn

N/A

Insider Ownership

15.49%

Institutional Own.

74.88%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NERLYNX Details Breast cancer, Cancer, ER+/HER2- breast cancer, Solid tumor/s	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NERLYNX Details Breast cancer, Sexual desire disorder, Sexual dysfunction	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Alisertib Details Cancer, Small cell lung cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Alisertib Details ER+/HER2- breast cancer, Breast cancer, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trastuzumab Emtansine (T-DM1) With Neratinib Details Breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Alisertib (2 combo trials) Details Breast cancer, ER+/HER2- breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Neratinib Details Lung cancer, Non-small cell lung carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Neratinib (HKI-272) + fulvestrant + trastzuzumab Details Metastatic breast cancer, Breast cancer, Metastatic breast cancer to brain	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Neratinib Details Cervical cancer, Infectious disease, Catheter related blood stream infections	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Neratinib Details Bile duct disease, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Alisertib Details Cancer, Non-small cell lung carcinoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Alisertib+pembrolizumab Details Head and neck squamous cell carcinoma, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.